Pathogen-Sensing Plasmacytoid Dendritic Cells Stimulate Cytotoxic T-Cell Function in the Atherosclerotic Plaque
Through Interferon-␣ A therosclerotic plaque inflammation is a well-established risk factor for rupture of the protective cap, subsequent thrombotic vessel occlusion, and acute coronary syndrome (ACS). [1] [2] [3] Accordingly, recruitment of lymphocytes and antigen-presenting cells to the atheroma is a critical event in the transition of a stable atherosclerotic lesion to a vulnerable plaque. 4 Although plaque-residing macrophages have been recognized as participants in the tissue injury leading to plaque destabilization, it has recently become clear that T cells also have tissue-injurious effector functions. 5 In particular, plaque-infiltrating CD4 T cells have cytotoxic capability, harming endothelial cells (ECs) as well as vascular smooth muscle cells (VSMCs). 6 -8 It is unclear how such T cells are activated in the plaque environment.
Dendritic cells (DCs) residing in the plaque may facilitate in situ T-cell activation. 9 DCs activate T cells by presenting
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antigen and providing costimulatory signals. DCs also affect T cells in an antigen-independent way by secreting cytokines, such as interleukin (IL)-12, which regulate the recruitment of plaque-infiltrating CD4 T cells. 10 DCs colocalize with T cells in the plaque, emphasizing their potential role in modulating T-cell function in vivo. 11, 12 The presence of DCs in ruptureprone areas of the atheroma raises the possibility that they interfere directly with tissue-damaging effector pathways. 9, 12 The capacity of DCs to stimulate T cells depends crucially on their stage of maturation. Toll-like receptors (TLR) provide a powerful mechanism of DC maturation by recognizing pathogen-associated molecular patterns (PAMPs) that signal "danger" imposed by infection or tissue damage. Overexpression of TLR4 on circulating antigen-presenting cells in ACS and expression of TLR1, TLR2, and TLR4 in the atherosclerotic plaque have been described. [13] [14] [15] [16] Candidate TLR ligands in the atherosclerotic plaque include microbes and (modified) autoantigens such as human heat shock protein 60 and oxidized low-density lipoprotein. [17] [18] [19] To date, studies have focused on CD11 ϩ myeloid DCs in atherosclerotic plaques. However, DCs also include another major subtype, CD11
Ϫ CD123 high plasmacytoid DCs (pDCs), which express TLR7 and TLR9. 20 Oligodeoxynucleotides containing particular CpG motifs (CpG ODN) typically found in microbial DNA are recognized by TLR9 and facilitate abundant interferon (IFN)-␣ production. 20 IFN-␣ is best known for its vital function in host immune responses that protect from infections. Specifically, IFN-␣ enhances cytotoxicity of CD8 and natural killer cells 21 and induces the expansion and activation of Th1-polarized CD4 T cells. 22, 23 IFN-␣ amplifies the ability of CD4 T cells to kill tumor cells. 24 Proapoptotic effects of CD4 T cells have recently been implicated in tissue-injurious responses in atherosclerotic plaques. 25 TNF-related apoptosis-inducing ligand (TRAIL) is expressed on CD4 T cells and binds to death receptor (DR)5, which is upregulated on stressed VSMCs. 8 DR5 ligation initiates the death pathway leading to VSMC apoptosis, a mechanism proposed to contribute to weakening of the fibrous cap. 26 -28 We examined whether pDCs have immunoregulatory functions in the atherosclerotic plaque and respond to PAMPs. We further investigated the role of IFN-␣ in regulating T-cell function through the induction of TRAIL, a powerful mediator of apoptosis implicated in cell death associated with plaque vulnerability.
Methods

Study Population
Blood was drawn from 31 patients (61% male, aged 55Ϯ10 years) with ACS (32% ST-elevation myocardial infarction) at admission. Patients with infectious, autoimmune, or neoplastic disease were ineligible. Thirty-one sex-and age-matched individuals without cardiovascular disease served as controls. Thirty carotid artery specimens were collected from patients undergoing endarterectomy procedures (Table I in the online-only Data Supplement). We determined atherosclerotic plaque vulnerability using a score modified from Depre et al 29 and Naghavi et al. 4 The size of the lipid core (0 to 2 points), the density of the inflammatory infiltrate (0 to 2 points), and the presence of residual thrombus (0 to 1 point) were determined in each plaque by macroscopic and microscopic analysis and semiquantified with the use of ImageJ (National Institutes of Health). Plaques with a score Ն3 were classified as vulnerable. Twelve morphologically atheroma-free parts of the specimens were used as controls. The Emory University Institutional Review Board approved all protocols, and appropriate consent was obtained.
Immunohistochemistry
Frozen carotid plaque tissues were cut into 5-m sections, fixed in acetone for 10 minutes, and dried. Endogenous peroxidase was blocked, and 5% of the appropriate animal serum was added to inhibit nonspecific staining. Slides were stained with the following antibodies for 1 hour at room temperature: mouse anti-human IFN-␣ (1:400; BD Pharmingen, San Jose, Calif), mouse anti-human CD123 for pDCs (1:100; BD Pharmingen), mouse anti-human TLR9 (1:100; Imgenex, San Diego, Calif), mouse anti-human CD3 for T cells (1:200 
Quantitative Reverse Transcriptase Polymerase Chain Reaction
Total RNA was isolated from shock-frozen endarterectomy and cell culture samples with the use of TRIzol (Invitrogen Life Technologies, Grand Island, NY) and transformed into cDNA with avian myeloblastosis virus reverse transcription (RT) (Roche Molecular Biochemicals). cDNA was amplified with primers specific for IFN-
, as described elsewhere. 20 Amplifications were performed in a Mx3000 polymerase chain reaction (PCR) machine (Stratagene, Cedar Creek, Tex) under the following cycling conditions: denaturation at 94°C for 10 minutes, followed by 40 cycles at 95°C for 30 seconds, 55°C for 60 seconds, and 72°C for 60 seconds. For each sample, PCR reactions were done in triplicate. The level of gene expression was determined by interpolation with a standard curve. cDNA copy numbers are expressed relative to 2ϫ10 5 ␤-actin copies.
Stimulation of Explanted Atherosclerotic Plaque Tissue
Fresh tissue from 6 soft lipid-rich carotid plaques was cut into small pieces. For each plaque, equal numbers of nonadjacent plaque pieces were randomly distributed into wells of a 48-well plate filled with RPMI medium that contained 10% fetal calf serum. Tissue fragments were stimulated with 100 g/mL synthetic CpG ODN (2006, TCGTCGTTTTGTCGTTTTGTCGT) for 24 hours. Stimulations were done in duplicate. After stimulation, tissue was shock-frozen for RNA isolation. In addition, IFN-␣ was measured in supernatants with an enzyme-linked immunosorbent assay (PBL Biomedical Laboratories, Piscataway, NJ).
Cells
Peripheral blood mononuclear cells were isolated from fresh blood with the use of Ficoll-Hypaque (Amersham Biosciences, Piscataway, NJ). CD4 T cells were isolated by negative selection (RosetteSep, StemCell Technologies, purity Ն94%). T-cell lines were isolated from carotid artery plaques by culturing tissue fragments with 50 U/mL recombinant IL-2 (Proleukin Chiron, Emeryville, Calif). Every 7 days, tissue-derived T cells were stimulated with 1ϫ10 6 /mL irradiated peripheral blood mononuclear cells, 1.5ϫ10 5 /mL irradiated Epstein-Barr virus-transformed B cells, 30 ng/mL anti-CD3 monoclonal antibody (Ortho Diagnostics), and 50 U/mL recombinant human IL-2. Tissue-derived CD4 T cells were memory T cells and lacked CD28 (data not shown). T cells were stimulated for 2 hours with IFN-␣ (200 U/mL, PBL, Biomedical Laboratories) or with 250 ng/mL anti-CD3 monoclonal antibody in the presence of FcRII ϩ P815 cells. Human coronary smooth muscle cells (SMCs) (Cambrex, Walkersville, Md) were grown in SmGM-2 smooth muscle medium (Cambrex).
Flow Cytometry
Multicolor flow cytometry analysis was performed by staining peripheral blood mononuclear cells and T cells for 30 
Apoptosis Assays
Confluent coronary SMCs grown in collagen-coated 96-well plates were pretreated for 1 hour with the nuclear binding dye 6Ј-diamidino-2-phenylindole (DAPI) (1 g/mL; Sigma-Aldrich, St Louis, Mo). Freshly isolated T cells or resting T-cell lines pretreated for 2 hours with IFN-␣ (200 U/mL) were added at varying effectorto-target ratios for 4 hours at 37°C in phenol red-free RPMI medium supplemented with 2% fetal calf serum. Untreated T cells served as controls. Apoptosis was assessed as previously described, 8 and apoptotic nuclear changes determined by DAPI staining were confirmed by annexin V membrane staining (1 g/mL; Molecular Probes, Eugene, Ore). To inhibit TRAIL-mediated apoptosis, T cells were treated with a mouse anti-human TRAIL monoclonal antibody (25 g/mL, RIK-2, Becton Dickinson) or IgG 1 mouse control antibody before being added to coronary SMCs. Apoptosis rates observed in coronary SMCs without T cells (Ͻ5%) were subtracted. A minimum of 3 pictures per experiment were taken with a fluorescence microscope with 200-fold magnification and analyzed by an observer blinded for treatment using ImageJ (W. Rasband, National Institutes of Health).
Statistical Analysis
The normal distribution of data was tested with the KolmogorovSmirnov test. Normally distributed data were analyzed with t tests for independent samples or t tests for paired samples (eg, for stimulation data). In case of skewed distribution (eg, RT-PCR results), corresponding nonparametric tests (Mann-Whitney U tests or Wilcoxon signed rank tests) were used. Correlations were analyzed with the Pearson correlation coefficient. A general linear model procedure was used to analyze experiments with repeated measures (eg, various effector-to-target ratios in cytotoxic assays). All analyses were calculated with the use of the SPSS software package 12.0 for Windows (SPSS, Inc, Chicago, Ill). The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
IFN-␣-Producing pDCs in the Atherosclerotic Plaque
Sixteen of 30 atherosclerotic plaques (53%) contained cells staining positive for CD123, a marker typically expressed on pDCs. CD123 ϩ pDCs were located in the shoulder region ( Figure 1A) or at the base of the plaque ( Figure 1C ). In addition, IFN-␣-producing cells were restricted to these atheroma regions ( Figure 1B, 1D) . Double staining demonstrated that pDCs were the main source of IFN-␣ (Ͼ90%) (Figure 1C, 1D) . The number of pDCs was 10-fold higher in unstable than in stable plaques (PϽ0.0001; Figure 1E ). ECs, which can express low CD123 levels, were identified through the vWF marker and remained negative for IFN-␣ (data not shown).
IFN-␣ in the Vulnerable Atheroma
IFN-␣ production in the atherosclerotic plaque was confirmed at the transcription level by quantitative RT-PCR. Tissue extracts were prepared from 30 plaques and 12 unaffected parts of carotid arteries. Plaques showed higher concentrations of IFN-␣ transcripts than normal vessel walls (PϽ0.0001; Figure 2) . To assess the relation between plaque vulnerability and IFN-␣ tissue levels, endarterectomy samples were graded according to the presence of thrombus, lipid content, and density of the inflammatory infiltrate (TLI score). IFN-␣ mRNA levels were markedly higher in plaques with high TLI scores than in noninflamed, nonthrombosed plaques (PϽ0.0001; Figure 2 ).
The TLR9 Ligand CpG ODN Induces IFN-␣ in Atherosclerotic Plaques
Immunohistochemical staining revealed TLR9 expression in the atherosclerotic plaque ( Figure 3A) . TLR9 transcripts correlated closely with IFN-␣ production in atheroma tissue, Figure 1 . IFN-␣-producing plasmacytoid dendritic cells in the atherosclerotic plaque. Frozen sections from carotid atherosclerotic plaques were stained with anti-CD123 antibody, a marker for pDCs (A; DAB, brown, magnification ϫ200, barϭ200 m; C, Vector Red, immunofluorescence, magnification ϫ100, barϭ500 m; insets, magnification ϫ400) and anti-IFN-␣ antibody (B; DAB, brown, magnification ϫ200, barϭ200 m; D, DAB, brown, magnification ϫ100, barϭ500 m; insets, magnification ϫ400).
CD123
ϩ and IFN-␣-producing cells were found in the shoulder region (A and B) and at the plaque base (C and D). Double staining with anti-CD123 (C; Vector Red, immunofluorescence) and anti-IFN-␣ antibody (D; DAB, brown) was used to define pDCs as the main source of IFN-␣. Stains of serial sections for IFN-␣ and CD123 confirmed that IFN-␣ was primarily produced by pDCs ( Figure I in the online-only Data Supplement). IFN-␣-producing cells were negative for CD11c (data not shown).
Numbers of CD123
ϩ pDCs were counted in 3 sections of each plaque (E). Plaque stability was categorized on the basis of the size of the lipid core, the presence of residual thrombus, and the density of the cellular infiltrate, as described in Methods.
indicating a possible role for TLR9 in the activation of plaque-residing pDCs (rϭ0.83, PϽ0.0001; Figure 3B ). To assess whether TLR9 in the lesion mediates responses to PAMPs, we stimulated plaque tissue with the macromolecule CpG ODN. Twenty-four fresh tissues from 6 lipid-rich plaques were examined in organ culture. Two tissue pieces from each plaque were randomly selected for stimulation with CpG ODN (nϭ12), and 2 pieces from each served as controls (nϭ12). CpG ODN stimulation resulted in a 2.5-fold increase of IFN-␣ mRNA levels compared with unstimulated control tissue (Pϭ0.03; Figure 3C ). In addition, IFN-␣ concentrations secreted into the supernatant were significantly higher in the CpG ODN-stimulated tissues (Pϭ0.007; Figure 3D ). In contrast, CpG ODN stimulation of stable plaques failed to induce IFN-␣ secretion (nϭ12 per group; Pϭ0.57). Figure 4C ). In addition, plaque tissue activation with CpG ODN was associated with a significant increase in TRAIL mRNA compared with unstimulated controls (nϭ12 per group) (Pϭ0.004; Figure 4D ).
IFN-␣ Induces TRAIL on CD4 T Cells
Immunomodulatory effects of IFN-␣ in CD4 T cells were examined in peripheral blood CD4 T cells collected from 31 ACS patients. Two hours of stimulation was sufficient to upregulate TRAIL surface expression on CD4 T cells by 10-fold (PϽ0.0001; Figure 4E and 4F). Remarkably, IFN-␣ much more efficiently brought TRAIL to the T-cell surface than did triggering of the T-cell receptor through anti-CD3 antibody ( Figure 4E ). IFN-␣ exposure not only enhanced TRAIL surface expression, but it also markedly increased transcription of the TNF-like molecule (Pϭ0.009; Figure  4G ).
IFN-␣-mediated TRAIL upregulation on CD4 T cells was not unique for ACS patients. Rather, peripheral blood CD4 T cells collected from age-and sex-matched controls responded similarly. However, IFN-␣-induced TRAIL upregulation in plaque-derived CD4 T cells was more pronounced, with Ͼ90% of CD4 T cells positive for TRAIL (data not shown).
IFN-␣ Induces TRAIL-Mediated SMC Apoptosis
To explore the functional relevance of IFN-␣-induced TRAIL expression on CD4 T cells, we investigated the death-inducing functions of such CD4 T cells. Coronary SMCs, which express the TRAIL receptor DR5, were chosen as targets. Plaque-derived CD4 T cells were added to coronary SMC monolayers for 4 hours at different effector to target ratios. CD4 T cells induced coronary SMC apoptosis very effectively ( Figure 5A ). Coronary SMC apoptosis was quantified by assessing the frequency of cells with typical nuclear changes of apoptosis through DAPI staining and by staining with the apoptosis mem- 
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Interferon-␣ in the Atherosclerotic Plaquebrane marker annexin. As shown in Figure 5B , coronary SMCs with intense DAPI staining of the nucleus double stained for annexin. IFN-␣ amplified CD4 T-cell killing ability at all effector to target ratios (Pϭ0.002; Figure 5A ). Incubating coronary SMCs with IFN-␣ alone did not induce apoptosis. Using peripheral CD4 T cells from 10 ACS patients, we found a consistent increase of coronary SMC apoptosis after pretreating CD4 T cells with IFN-␣ (Pϭ0.0003; Figure 5C ). Detection of apoptotic coronary SMCs by annexin confirmed enhanced coronary SMC apoptosis with IFN-␣-pretreated CD4 T cells compared with untreated CD4 T cells (23Ϯ3.5% versus 15Ϯ2.6%; Pϭ0.005). Apoptosis could be inhibited by blocking with a neutralizing antibody specific for TRAIL in a dosedependent manner (Pϭ0.0002; Figure 5D ), documenting that CD4 T cells utilize TRAIL to trigger the SMC death pathway.
Discussion
CD4 T cells, the dominant type of lymphocytes in the atherosclerotic plaque, 30 have powerful tissue-damaging functions. They are able to activate macrophages via IFN-␥, 31, 32 inducing the release of matrix-degrading proteases. CD4 effector cells also have the ability to directly kill plaque-residing cells, including ECs and VSMCs. 7, 8 T cells are generally controlled through TCRs by recognizing antigen, yet a unique subset of CD4 T cells characterized by CD28 loss can be activated independently from TCRs. 5 In this report we provide data that IFN-␣ released in the plaque controls CD4 T-cell cytotoxic effector functions. The efficacy of IFN-␣ in rapidly modulating CD4 T-cell function is not only independent from antigen recognition; it also outperforms signals initiated by TCR cross-linking. Indeed, plaqueresiding CD4 T cells are remarkably sensitive to the IFN-␣ action. IFN-␣ biases CD4 T cells toward harming matrix- producing and structure-stabilizing VSMCs and thus emerges as a critical contributor to plaque instability.
The innate cytokine IFN-␣ is released when DCs sense microbial products, mechanistically linking host infections and plaque destabilization. The ability of IFN-␣ to profoundly modulate T-cell effector functions immediately raises the question of the source of IFN-␣ in the plaque environment. Immunohistochemical studies (Figure 1 ) in the atheroma support the notion that pDCs are the dominant producer of IFN-␣. 33, 34 Most plaque tissues contain IFN-␣-producing pDCs preferentially located in the shoulder region. This observation is in accordance with recent data indicating that pDCs are not limited to lymphoid organs but are often encountered in inflamed skin or lung tissues. 33, 35 CCL5 and CCL3 abundantly expressed in atherosclerotic plaques 10 may attract pDCs expressing their corresponding chemokine receptor CCR5. 36 Whether DC recruitment reflects local infection or is a consequence of chronic inflammation remains to be investigated.
A close correlation between IFN-␣ and TLR9 transcripts indicated the relevance of TLR9 triggering for activating plaque pDCs. Upregulation of IFN-␣ transcripts and protein after stimulation of plaque explants with the TLR9 ligand CpG ODN confirmed the functional relevance of TLR9 triggering for activation of IFN-␣-producing cells in the intact tissue. With regard to human pathogens, viruses such as herpes simplex virus type 1, cytomegalovirus, and influenza virus stimulate pDCs to produce IFN-␣ via well-understood signaling pathways involving myeloid differentiation factor 88 and IFN regulatory factor 7. 34,37,38 IFN-␣ production also plays a critical role in response to bacterial infections. 39 The sensitivity of IFN-␣-producing cells to multiple pathogens correlates well with the concept of the infectious burden, emphasizing the importance of numerous infections rather than the role of a single and specific pathogen. 40 Multiple suspects have been found in the plaque, [41] [42] [43] but data presented here would also allow systemic disease to modulate plaque inflammation. Circulating "danger" signals may trigger pDCs to produce IFN-␣, potentially explaining the link between acute infections and inflammatory activation of vulnerable plaques. 44 IFN-␣ released in close vicinity to lymphocytes in the atheroma effectively induced the expression of the apoptosis mediator TRAIL on CD4 T cells. Additional upregulation of TRAIL transcripts indicates that IFN-␣ not only induces surface expression of vesicle-stored TRAIL but also its transcription. As previously shown, CD4 T cells from ACS patients kill coronary SMCs in a TRAIL-dependent manner. 8 In this report we demonstrate that IFN-␣ stimulation of CD4 T cells from ACS patients translates into even more pronounced coronary SMC apoptosis, a process that could be blocked by TRAIL-specific antibodies. Coronary SMCs abundantly express DR5 and are therefore susceptible to TRAIL. 8 VSMC loss may result in structural weakening and rupture of the atheroma cap. 26 -28 Moreover, apoptotic VSMCs induce thrombin generation, 45 accelerating the thrombotic occlusion of the artery. 28 TRAIL may also induce apoptosis of other plaque-residing cells such as ECs. 46 When the unique and powerful ability of IFN-␣ to induce TRAIL expression on CD4 T cells is considered, IFN-␣-induced, T cell-mediated apoptosis of plaque-residing cells appears to be an important mechanism in plaque destabilization. The presence of IFN-␣-producing pDCs in the plaque shoulder and the association of IFN-␣ transcript with plaque vulnerability emphasize the potential role of IFN-␣ in inducing plaque rupture. Immunoregulatory function for IFN-␣ in coronary artery disease is also suggested by the recent recognition that complications of coronary disease are markedly accelerated in systemic lupus erythematosus, a syndrome characterized by the overexpression of IFN-␣. 47, 48 The association of immune effector functions critically involved in host protection, such as the potent antiviral and antitumor effects of IFN-␣ via TRAIL-mediated killing of tumor cells or infected cells, 24 with tissue injury reemphasizes the ambiguity of immune effector pathways. The coexistence of protective and harmful immune functions raises concerns about the cost-benefit ratio of therapeutic interventions targeting such pathways. Enhancing TRAIL-dependent immune reactions in cancer and hepatitis C may indeed put patients with coexisting advanced atherosclerosis at risk for plaque instability. Our data suggest a model of plaque injury in which pattern recognition receptors such as TLR9 respond to infectious molecular patterns from both viral and bacterial sources and amplify tissue-damaging immune responses in the inflamed plaque. By releasing IFN-␣, pDCs not only enhance host protection, but they also enable tissue-injurious effector functions that threaten the tissue integrity of the plaque. This mechanism of tissue damage requires the presence of IFN-␣-responsive CD4 T cells in the plaque and sensitivity by plaque-residing cells, including VSMCs and ECs, to TRAIL, a requirement that is met in unstable lesions. TLR9 ligands initiating a cascade of events leading to cellular loss in the plaque may be derived from local sources in the plaque but also from infections distant from the vessel wall lesion. Transient peaks in circulating PAMPs may be sufficient to trigger plaque inflammation and plaque disruption. Protection from plaque instability may therefore require shielding the host from infectious episodes. Similarly, targeting pathways relevant in the immune-mediated injury of the plaque holds the promise for novel therapeutic interventions.
